Palvella says Phase 3 SELVA substudy shows QTORIN rapamycin systemic exposure at least 40-fold below oral sirolimus

• Palvella Therapeutics announced three posters with new Phase 3 SELVA and market-analysis data, presented at Fall Clinical Dermatology 2026.
• Interview findings from SELVA indicated patients, caregivers, and clinicians reported meaningful symptom improvement with QTORIN rapamycin, with high satisfaction.
• A maximal-use substudy found low, steady systemic exposure with the topical rapamycin gel, supporting a potentially favorable safety profile versus oral use.
• A U.S. claims review estimated 154,986 diagnosed DSAP patients, positioning DSAP as a sizable orphan-market opportunity for QTORIN pitavastatin.
• An FDA NDA filing for QTORIN rapamycin in microcystic lymphatic malformations has been submitted; a DSAP Phase 2 study is expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120730PRIMZONEFULLFEED9843598) on October 12, 2026, and is solely responsible for the information contained therein.